Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 25, 2022 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics President to Join Expert Panel at the Fifth Annual DDR, ATR & PARP Inhibitors Summit

VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
January 06, 2022 17:01 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022

VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
December 21, 2021 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents

VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
November 23, 2021 17:25 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
November 16, 2021 08:30 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Partners with St. Baldrick’s Foundation to Research and Develop New Treatments for Childhood Bone Cancer

VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
November 11, 2021 09:20 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Presents at the 6th biennial Canadian Cancer Research Conference

VANCOUVER, British Columbia, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
October 21, 2021 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics to Present at the 6th biennial Canadian Cancer Research Conference

VANCOUVER, British Columbia, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
October 12, 2021 10:47 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Presents at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

VANCOUVER, British Columbia, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
October 07, 2021 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors

VANCOUVER, British Columbia, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSX-V: RKV) today announced that the Company has received notice of allowance from the...
September 16, 2021 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Presents Preclinical Data on novel kt-3000 Series Drug Candidates at JCA-AACR Precision Medicine International Conference

VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...